Related Experiment Video

Updated: Jun 20, 2026

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
04:50

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Published on: May 16, 2025

EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and

M J L Peters1, D P M Symmons, D McCarey

  • 1Department of Rheumatology, VU University Medical Centre, Amsterdam, The Netherlands.

Annals of the Rheumatic Diseases
|September 24, 2009
PubMed

Insights

Annual cardiovascular risk assessment is recommended for patients with rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis. Management should follow guidelines or the SCORE function, alongside aggressive inflammation suppression to reduce cardiovascular risk.

Area of Science:

  • Rheumatology and Cardiology
  • Inflammatory Arthritis
  • Cardiovascular Risk Management

Background:

  • Rheumatoid arthritis (RA), ankylosing spondylitis (AS), and psoriatic arthritis (PsA) are associated with increased cardiovascular (CV) risk.
  • Evidence for elevated CV risk is strongest in RA, but also present in AS and PsA.
  • Need for standardized CV risk management strategies in these patient populations.

Framework:

  • Development of evidence-based European League Against Rheumatism (EULAR) recommendations.
  • Multidisciplinary task force including rheumatologists, cardiologists, internists, and epidemiologists.
  • Systematic literature review following EULAR's standardized operating procedures.

Implementation:

  • Annual CV risk assessment recommended for RA patients; considered for AS and PsA patients.
  • Management of identified CV risk factors according to local guidelines or SCORE function.
  • Aggressive suppression of inflammatory disease activity to mitigate CV risk.

Implications:

  • Ten EULAR recommendations formulated for CV risk management in RA, AS, and PsA.
  • Differentiated strength of recommendations based on the compelling evidence for increased CV risk in RA.
  • Improved CV risk stratification and management strategies for patients with inflammatory arthropathies.
Abstract

Related Concept Videos

Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
Rheumatic Heart Disease IV: Nursing Management01:20

Rheumatic Heart Disease IV: Nursing Management

AssessmentA comprehensive assessment is essential in managing a patient with rheumatic heart disease (RHD). Begin with obtaining a detailed medical history, including recent streptococcal infections, a history of rheumatic fever, or previously diagnosed rheumatic heart disease. Assess the patient for symptoms such as fever, chest pain, widespread joint pain (arthralgia), tachycardia, pericardial friction rub, muffled heart sounds, heart murmurs, peripheral edema, subcutaneous nodules, and...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Rheumatic Heart Disease I: Introduction01:23

Rheumatic Heart Disease I: Introduction

Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...